New Trends and Advances in Molecular Targeted Therapy for Cancers

Dear Colleagues,

Conventional chemotherapy has evolved drastically over the past decade in order to address the longstanding challenge of cancer heterogeneity aiming for better progression-free survival. The development of targeted therapy that aims to inhibit specific targets/proteins has revolutionized the cancer therapy, leading to side-effect elimination and enhanced efficacy. With small-molecule inhibitors and monoclonal antibodies majorly constituting the majority of targeted cancer therapies, simultaneous effects on cancer cells and immune cells are achieved by nullifying major intrinsic resistance mechanisms. This also opens the venue for introducing novel treatment combinations and antibody-drug conjugates. 

This Special Issue aims to highlight the current landscape of targeted therapies against prevalent cancers, especially the ongoing combinational strategies that hold a promise of better outcomes and improved quality of life. This Special Issue will be providing a panoramic view of the existing options, its challenges, and future potential that will deepen our understanding regarding enhanced clinical benefits in cancer patients. 

We look forward to receiving your contributions.

Dr. Dhivya Sridaran
Prof. Dr. Jeremy M. Crook
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.